Role of poly (ADP-ribose) polymerase-1 and NF-kappaB as potential risk factor in the development of non-small cell lung cancer in Chinese individuals
暂无分享,去创建一个
[1] Ning-hua Cui,et al. Associations of PARP-1 variant rs1136410 with PARP activities, oxidative DNA damage, and the risk of age-related cataract in a Chinese Han population: A two-stage case-control analysis. , 2017, Gene.
[2] N. Corcoran,et al. Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis , 2016, Clinical Cancer Research.
[3] J. Rosińćzuk,et al. Quality of life of patients with lung cancer , 2016, OncoTargets and therapy.
[4] Dong-Wan Kim,et al. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations , 2015, Cancer research and treatment : official journal of Korean Cancer Association.
[5] M. Niyazoğlu,et al. Association of PARP-1, NF-κB, NF-κBIA and IL-6, IL-1β and TNF-α with Graves Disease and Graves Ophthalmopathy. , 2014, Gene.
[6] P. Ellis,et al. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. , 2013, Current oncology.
[7] D. Zhong,et al. The hOGG1Ser326Cys Polymorphism and Increased Lung Cancer Susceptibility in Caucasians: An Updated Meta-Analysis , 2012, Scientific Reports.
[8] Hongxia Ma,et al. Association between PARP‐1 V762A polymorphism and cancer susceptibility: a meta‐analysis , 2012, Genetic epidemiology.
[9] N. Garg,et al. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. , 2011, The American journal of pathology.
[10] T. Kielian,et al. Poly (ADP‐ribose) polymerases (PARPs) 1‐3 regulate astrocyte activation , 2008, Journal of neurochemistry.
[11] S. Bae,et al. Poly(ADP-ribose) polymerase (PARP) polymorphisms associated with nephritis and arthritis in systemic lupus erythematosus. , 2006, Rheumatology.
[12] T. Eisen,et al. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. , 2003, Mutagenesis.
[13] M. Moskowitz,et al. Poly(ADP‐ribose) polymerase‐1 activity promotes NF‐κB‐driven transcription and microglial activation: implication for neurodegenerative disorders , 2003, Journal of neurochemistry.
[14] V. Soldatenkov,et al. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase. , 2002, Cancer Research.
[15] T. Dawson,et al. Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.
[16] A. Chiarugi. Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. , 2002, Trends in pharmacological sciences.
[17] D. Comings,et al. Molecular heterosis: a review. , 2000, Molecular genetics and metabolism.
[18] A. Yakovlev,et al. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. , 2000, Advances in enzyme regulation.
[19] B. Stokes,et al. Peroxynitrite production and activation of poly (adenosine diphosphate‐ribose) synthetase in spinal cord injury , 1999, Annals of neurology.
[20] M. Hottiger,et al. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. , 2008, Frontiers in bioscience : a journal and virtual library.